|
Catalogue
Number
|
Product
|
Order number / Unit
|
|
|
9934
|
PSMA-617 (GMP)
|
Please inquire for customized
filling and bulk quantities.
|
|
|
Precursor for [68Ga/177Lu/90Y]PSMA-617
PSMA: prostate-specific membrane antigen
|
|
|
Manufactured according to GMP requirements for APIs for use in clinical trials (ICH Q7 chapter 19)
|
|
|
|
|
|
Molar Mass: 1042.1 (net peptide)
|
|
|
C49H71N9O16
|
|
|
CAS-RN not yet assigned
|
|
|
|
|
|
Colourless to off-white solid packaged in plastic vials
|
|
|
|
|
|
|
|
|
Purity: ≥ 98 %
|
|
|
Certificates:
CoA with ESI-MS and NMR (identity); HPLC (purity) ; GC (residual solvents); heavy metals content (ICP-MS); microbiology test
|
|
|
Chemical Name:
|
|
|
Synonymes:
2-[3-(1-Carboxy-5-{3-naphthalen-2-yl-2-[(4-{[2-(4,7,10-tris-carboxymethyl-1,4,7,10-tetraaza-cyclododec-1-yl)-acetylamino]-methyl}-cyclohexanecarbonyl)-amino]-propionylamino}-pentyl)-ureido]-pentanedioic acid
|
|
|
Literature:
Kratochwil C. et al. [177Lu]Lutetium-labelled PSMA ligand-induced remission in a patient with metastatic prostate cancer. Eur. J. Nucl. Med. Mol. Imaging. 2015, 42, 987-988.
|
|
|
Benesova M. et al. Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer. J. Nucl. Med. 2015, 56, 914-920.
|
|
|
|
|
|
|
|
|
|
|
|
date of product catalogue issue:
10 May 2017
|